SG11201804123VA - Modulators of kv3 channels to treat pain - Google Patents
Modulators of kv3 channels to treat painInfo
- Publication number
- SG11201804123VA SG11201804123VA SG11201804123VA SG11201804123VA SG11201804123VA SG 11201804123V A SG11201804123V A SG 11201804123VA SG 11201804123V A SG11201804123V A SG 11201804123VA SG 11201804123V A SG11201804123V A SG 11201804123VA SG 11201804123V A SG11201804123V A SG 11201804123VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- stevenage
- autifony
- bioscience
- pct
- Prior art date
Links
- 241000581479 Apodichthys Species 0.000 abstract 3
- 239000003054 catalyst Substances 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 239000002023 wood Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 241000566137 Sagittarius Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/30—Compounds having groups
- C07C43/315—Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1521751.6A GB201521751D0 (en) | 2015-12-10 | 2015-12-10 | Novel uses |
| PCT/GB2016/053879 WO2017098254A1 (en) | 2015-12-10 | 2016-12-09 | Modulators of kv3 channels to treat pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804123VA true SG11201804123VA (en) | 2018-06-28 |
Family
ID=55274489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804123VA SG11201804123VA (en) | 2015-12-10 | 2016-12-09 | Modulators of kv3 channels to treat pain |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11147813B2 (https=) |
| EP (1) | EP3386506B1 (https=) |
| JP (3) | JP7149847B2 (https=) |
| KR (1) | KR102812887B1 (https=) |
| CN (2) | CN108472288B (https=) |
| AU (1) | AU2016367239B2 (https=) |
| BR (1) | BR112018011700B1 (https=) |
| DK (1) | DK3386506T3 (https=) |
| EA (1) | EA038059B1 (https=) |
| ES (1) | ES2974902T3 (https=) |
| FI (1) | FI3386506T3 (https=) |
| GB (1) | GB201521751D0 (https=) |
| HR (1) | HRP20240497T1 (https=) |
| HU (1) | HUE066879T2 (https=) |
| IL (1) | IL259717B (https=) |
| MX (1) | MX385578B (https=) |
| PL (1) | PL3386506T3 (https=) |
| PT (1) | PT3386506T (https=) |
| SG (1) | SG11201804123VA (https=) |
| WO (1) | WO2017098254A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| EP3555073A1 (en) | 2016-12-16 | 2019-10-23 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
| WO2018220762A1 (ja) * | 2017-05-31 | 2018-12-06 | 大塚製薬株式会社 | ピリミジン化合物 |
| KR102854594B1 (ko) * | 2018-10-16 | 2025-09-02 | 오티포니 세라피틱스 리미티드 | 신규한 화합물 |
| US12358901B2 (en) | 2018-10-16 | 2025-07-15 | Autifony Therapeutics Limited | KV3 modulators |
| AR116898A1 (es) * | 2018-10-30 | 2021-06-23 | H Lundbeck As | DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVADORES DE CANALES DE POTASIO Kv3 |
| MY210184A (en) | 2018-11-30 | 2025-08-31 | Otsuka Pharma Co Ltd | Heterocyclic compounds for the treatment of epilepsy |
| BR112022013339A2 (pt) | 2020-02-06 | 2022-09-13 | Autifony Therapeutics Ltd | Moduladores de kv3 |
| KR20240046748A (ko) | 2021-08-10 | 2024-04-09 | 오티포니 세라피틱스 리미티드 | 칼륨 채널 조절제 |
| CN113788741B (zh) * | 2021-09-28 | 2023-12-29 | 大连九信精细化工有限公司 | 一种制备2-环丙基苯酚衍生物的方法 |
| WO2024121552A1 (en) | 2022-12-06 | 2024-06-13 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102083792A (zh) | 2008-06-06 | 2011-06-01 | Ucb医药有限公司 | 包含环丁氧基的化合物 |
| EP2509961B1 (en) | 2009-12-11 | 2016-03-09 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
| EA023768B1 (ru) * | 2010-12-06 | 2016-07-29 | Отифони Терапеутикс Лимитед | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ |
| GB201209986D0 (en) | 2012-06-06 | 2012-07-18 | Autifony Therapeutics Ltd | Novel compounds |
| CN103596943B (zh) | 2011-06-07 | 2016-10-12 | 奥蒂福尼疗法有限公司 | 用作kv3抑制剂的乙内酰脲衍生物 |
| EP2788339B1 (en) * | 2011-12-06 | 2016-03-09 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| US9669030B2 (en) | 2012-05-22 | 2017-06-06 | Autifony Therapeutics Limited | Hydantoin derivatives as Kv3 inhibitors |
| US9422252B2 (en) * | 2012-05-22 | 2016-08-23 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
| WO2013182851A1 (en) | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201522179D0 (en) | 2015-12-16 | 2016-01-27 | Autifony Therapeutics Ltd | Novel compounds |
-
2015
- 2015-12-10 GB GBGB1521751.6A patent/GB201521751D0/en not_active Ceased
-
2016
- 2016-12-09 HR HRP20240497TT patent/HRP20240497T1/hr unknown
- 2016-12-09 MX MX2018007074A patent/MX385578B/es unknown
- 2016-12-09 HU HUE16813020A patent/HUE066879T2/hu unknown
- 2016-12-09 AU AU2016367239A patent/AU2016367239B2/en active Active
- 2016-12-09 DK DK16813020.1T patent/DK3386506T3/da active
- 2016-12-09 PT PT168130201T patent/PT3386506T/pt unknown
- 2016-12-09 US US16/060,714 patent/US11147813B2/en active Active
- 2016-12-09 ES ES16813020T patent/ES2974902T3/es active Active
- 2016-12-09 JP JP2018529633A patent/JP7149847B2/ja active Active
- 2016-12-09 EA EA201891377A patent/EA038059B1/ru unknown
- 2016-12-09 BR BR112018011700-5A patent/BR112018011700B1/pt active IP Right Grant
- 2016-12-09 FI FIEP16813020.1T patent/FI3386506T3/fi active
- 2016-12-09 SG SG11201804123VA patent/SG11201804123VA/en unknown
- 2016-12-09 CN CN201680072639.8A patent/CN108472288B/zh active Active
- 2016-12-09 PL PL16813020.1T patent/PL3386506T3/pl unknown
- 2016-12-09 CN CN202410102663.8A patent/CN118267386A/zh active Pending
- 2016-12-09 EP EP16813020.1A patent/EP3386506B1/en active Active
- 2016-12-09 WO PCT/GB2016/053879 patent/WO2017098254A1/en not_active Ceased
- 2016-12-09 KR KR1020187017088A patent/KR102812887B1/ko active Active
-
2018
- 2018-05-30 IL IL259717A patent/IL259717B/en active IP Right Grant
-
2021
- 2021-09-10 US US17/472,493 patent/US11944623B2/en active Active
-
2022
- 2022-06-30 JP JP2022106247A patent/JP2022141699A/ja active Pending
-
2024
- 2024-01-30 US US18/427,639 patent/US20250017925A1/en not_active Abandoned
- 2024-09-06 JP JP2024154042A patent/JP2025003958A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804123VA (en) | Modulators of kv3 channels to treat pain | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201811074RA (en) | Nant cancer vaccine | |
| SG11201804294WA (en) | Tank-binding kinase inhibitor compounds | |
| SG11201901995TA (en) | Crystalline and salt forms of ppar agonist compounds | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201809537VA (en) | Urea motif containing compounds and derivatives thereof as antibacterial drugs | |
| SG11201809702SA (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201808306PA (en) | Treatment of cancer with tg02 | |
| SG11201804936UA (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201900132QA (en) | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer | |
| SG11201900471VA (en) | Combination therapy for copd | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors |